Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4256984 · 3 trials · 2 indications
A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4256984 | EXPERIMENTAL | LY4256984 administered intrathecally (IT) |
| LY4256984 (Cohorts 1-4) | EXPERIMENTAL | Multiple ascending doses (MAD) of LY4256984 administered intrathecally (IT) |
| Placebo | PLACEBO_COMPARATOR | Administered IT |
| Name | Type | Description |
|---|---|---|
| LY4256984 | DRUG | Administered IT |
| Placebo | DRUG | Administered IT |
Participants must meet eligibility criteria in the \[L0U-MC-OLMP\] screening protocol before entry into the treatment study. Inclusion Criteria: * Have completed the main treatment period/phase as well as any off-treatment period/phase of Study OWAA, the parent study for this ISA. Exclusion Crite...
LY4256984 is an investigational small molecule being developed for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. It is currently in Phase 1 clinical trials studying participants with sporadic ALS. The drug is being evaluated in placebo-controlled, double-blind studies to assess its safety and tolerability in this patient population.
LY4256984 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the NYSE under the ticker symbol LLY. The company is sponsoring multiple Phase 1 clinical trials of LY4256984 in participants with sporadic amyotrophic lateral sclerosis across several countries including Belgium, Canada, Germany, Netherlands, and Spain.
LY4256984 is in Phase 1 clinical development for amyotrophic lateral sclerosis (ALS). It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trials are recruiting participants with sporadic ALS to evaluate the drug's safety, tolerability, and pharmacokinetics in a controlled clinical setting.
LY4256984 is being studied in three Phase 1 clinical trials: NCT07100119, a study in participants with sporadic ALS; NCT07571174, a substudy in participants with sporadic ALS; and NCT07571200, a master protocol study in participants with ALS. All three trials are actively recruiting participants in Belgium, Canada, Germany, Netherlands, and Spain.
LY4256984 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials for amyotrophic lateral sclerosis (ALS). The drug is being studied in placebo-controlled, double-blind trials to evaluate its safety and tolerability in participants with sporadic ALS, but it has not yet completed the clinical development process required for regulatory approval.